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ABSTRACT
Background
Systematic symptom reporting by patients and the use
of questionnaires such as the Edmonton Symptom As-
sessment System (ESAS) have potential to improve
clinical encounters and patient satisfaction. We review
findings from published studies of the ESAS to guide
use of the system and to focus research.
Methods
A systematic search for articles from 1991 through
2007 found thirty-nine peer-reviewed papers from 25
different institutions, thirty-three of which focused on
patients with cancer. Observations, data, and statistics
were collated according to relevance, reliability, va-
lidity, and responsiveness.
Results
Findings apply predominantly to symptomatic pallia-
tive patients with advanced cancer who were no longer
receiving active oncologic therapies. Uncertainty about
summarizing findings arises from frequent modifica-
tion of the ESAS (altered items, scales, and time peri-
ods). Overall, reliability is established for daily
administration. Scores are skewed, with a floor effect,
but the relative order of symptoms by mean scores is
similar across studies. Emotional symptoms are poorly
captured by the depression and anxiety items. An equally
weighted summation of scores may estimate a con-
struct of “physical symptom distress,” which in turn is
related to performance status, palliative goals, quality
of life, and well-being.
Conclusions
The ESAS is reliable, but it has restricted validity, and
its use requires a sound clinical process to help inter-
pret scores and to give them an appropriate level of
attention. Research priorities are to further develop the
ESAS for assessing a greater number of important physi-
cal symptoms (and to target “physical symptom
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distress”), and to develop a similar instrument for emo-
tional symptoms.
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1. INTRODUCTION
Patients with cancer experience many physical and
emotional symptoms. When these patients self-report
their symptoms, the prevalence and severity data for
the symptoms tend to vary significantly from those iden-
tified by health care providers and from the data re-
corded in charts and on research forms 1. Patients may
be better able to identify and assess symptoms that
have a larger subjective component—for example, pain
or fatigue. Discrepancies in clinical priorities and symp-
tom subjectivity may explain the dissatisfaction with
physical care registered by 20% of cancer patients in
Ontario, and the dissatisfaction with emotional care
registered by 43% (2004–2006) 2. Systematic symp-
tom assessment tools completed by patients just before
ambulatory and in-hospital clinical visits have a poten-
tial to shape encounters and may improve rapport, effi-
ciency, informed consent, administered care, and patient
compliance, and likewise, satisfaction with care.
A number of screening instruments for symptoms
have been introduced. These range from single-focus
tools to instruments that target multiple domains, and
from checklists to multiple-item indices with complex
scoring methods. For instance, some measures aggre-
gate items into a summary score that may be linked to
a concept such as distress or quality of life (QOL). For
patients with cancer, only a limited set of instruments
are available for possible clinical use 3. These include
the Distress Thermometer (DT) 4, the Memorial Symp-
tom Assessment Scale (MSAS) 5, and the Edmonton
Symptom Assessment System (ESAS) 6. Tools more
prevalent in research contexts include the European
Organization for Research and Treatment of Cancer
(EORTC) tools 7 and the Functional Assessment of Can-
cer Therapy (FACT) tools 8, although these may also be
used in clinical practice.ESAS REVIEW
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The ESAS was first described in 1991 6 as a way to
audit symptoms for patients on palliative care wards
daily. This single-page screening tool has been praised
for its brevity and ease of use 9, and is frequently de-
scribed as practical, reliable, and valid 10–18. Cancer
Care Ontario recently implemented the ESAS in can-
cer clinics across the province, intending administra-
tion at every patient visit 19. Some clinics in Ontario
already have experience with the ESAS, but others have
yet to use it as a process of care. Implementation re-
quires interpreting the ESAS and having acceptable re-
sponses to the information it provides.
The purpose of the present review is to summa-
rize what is known about the ESAS; to understand its
reliability, validity, and interpretive schemes; to guide
its use by patients and health care providers; and to
prioritize research.
2. METHODS
In January 2008, we conducted a systematic search of
the MEDLINE and PsycINFO electronic databases for
published papers containing “Edmonton Symptom As-
sessment” in the title or abstract. A hand search was
conducted for articles in personal files and for cita-
tions in papers, textbooks, and reference books. More
than 130 relevant articles and abstracts were identi-
fied, of which thirty-nine were primary studies pub-
lished as complete peer-reviewed papers, representing
25 different institutions. Of the thirty-nine papers, thir-
teen were from Canada 6,11,20–30; eight were from the
United States 12–14,18,31–34; eight were from Scandi-
navia (Sweden 15,35–37, Denmark 38–39, Norway 40,
Finland 16); two were from Western Europe (Nether-
lands 41, United Kingdom 42); five were from southern
Europe (Switzerland 43, Italy 17,44–46); two were from
Australia 47,48; and one was from Asia 49.
Data on patient demographics, cancer types, clini-
cal contexts (for example, in-hospital, advanced dis-
ease), manner of use or modification of the ESAS,
observed reliability and validity, and other observations
relevant to use of the instrument were systematically
extracted from each paper.
3. RESULTS
3.1 Population Characteristics
Of the thirty-nine papers, thirty-three represented stud-
ies conducted predominantly or exclusively in patients
with cancer. The remaining six papers included other
populations (patients with AIDS 13, renal disease 24, be-
nign disease 29, and cardiorespiratory diseases 18,22,34).
Sample sizes in the thirty-three oncologic studies
ranged from 32 to 1296 subjects, for a total in excess
of 5000 patients. However, eleven of the thirty-three
studies reported some data for the same patients:
Sunnybrook Cancer Centre in Canada 25–28, Bispebjerg
Hospital in Denmark 38–39, Linkoping Hospital in Swe-
den 15,35,36, and Yale University 18,34. For the patients
described in the thirty-three papers, median age ranged
from 53 to 74 years, and men were in a slight majority
overall. Most studies used the ESAS in its English or
northern European language versions, and most of the
study subjects were white.
Of the thirty-three oncologic studies, twenty-nine
were conducted in palliative populations with advanced
cancer, and more than one half of these studies admin-
istered the ESAS exclusively to hospitalized patients
for acute admission, for time-limited and long-term
admissions, when in intensive care, and with symp-
tom acuity or with stable disease. The most frequent
diagnoses were lung and gastrointestinal malignancies,
although many other cancer types were represented.
The overall distribution was perhaps typical of a pal-
liative population. In the non-hospital but palliative
context, most subjects were at home 17,18,22,25–
30,32,34,36,40,47 or at a hospice 48. Overall, the “extreme”
condition of the subjects is reflected in the descrip-
tions provided in the papers themselves: disease was
“advanced,” patients were “terminally ill,” symptoms
were “moderate” to “severe” (justifying hospitaliza-
tion), performance status was intermediate-to-low
[median Karnofsky performance status (KPS): 40–70],
and reduced cognitive functioning was present in some
patients. Longitudinal studies reported that one half of
all patients dropped out from questionnaire completion
within weeks during follow-up. Where reported, me-
dian survival was less than 3 months.
Of the twenty-nine studies in palliation, five in-
cluded patients receiving active cancer therapies apart
from supportive and palliative care: four targeted pa-
tients managed with radiotherapy (of which 75% were
outpatients 25–28), and one studied survival with pallia-
tive chemotherapy 44. Finally, the remaining four of
the thirty-three oncologic studies focused on less-pal-
liative situations: one study looked at participants of
three randomized trials, including 48 survivors of can-
cer 14; one included a “general cancer population” of
240 patients being managed with curative intent 31; one
included patients having lymphoma or leukemia (al-
though, on average, more than 2 years after initial di-
agnosis and in hospital) 33; and one examined patients
between 6 and 36 months after initial diagnosis 37.
3.2 Face and Content Validity
Despite relative uniformity of the clinical contexts in
which the ESAS was administered, its format and the
symptoms that were included varied. Authors described
these as “modifications” that included changed items,
added items, and changes in descriptors or scales.
Typically, symptom scales were presented hori-
zontally—a presentation that may make the ESAS seem
simple and consistent to patients 47. However, the ori-
entation of visual analog scales (horizontal vs. vertical)RICHARDSON and JONES
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may have a critical influence on measurement. This
factor requires further investigation with the ESAS 50.
Noticeably distinct from the original ESAS was replace-
ment of a visual analog scale (0–100 mm) with cat-
egorical numbered scales (0–10). One study further
reduced scales to 5 categories 12, and others reduced
them to 4 categories 18,34. No comparisons of these
versions of scales have been published, although some
authors have claimed that visual analog and numeric
scales elicit similar scoring 51. Numeric scales may
be more acceptable to patients, more efficient to
score 31,42,48, and applicable from bedside care to tel-
ephone follow-up 25.
Another noticeable modification to the ESAS was
the period over which symptoms were to be scored.
This period has varied from as short as “at present” or
within the past few hours 51, up to several days 48 or
weeks 25,37. Most studies administered the ESAS daily,
without explicitly defining a period of assessment. The
importance of being specific is clear for the “severe
pain” item, where “severe pain” is understood by pa-
tients to mean “worst pain” rather than some other sta-
tistic or estimate 31, and the influence of time period
on all items remains a concern.
The number of symptoms in the ESAS has varied
from 8 items (in the original version) to more than 11—
typically with 1 “open” scale for an additional rater-
selected symptom. The most recent version of the ESAS
includes 9 symptoms—(in order) pain, tiredness, nau-
sea, depression, anxiety, drowsiness, appetite, well-
being, and shortness of breath (SOB) 52. A score of 10
is described as the “worst possible” symptom. This
recent ESAS version includes 7 of the 12 most com-
mon symptoms identified in large surveys 9,53,54. These
symptoms may be common, but they need not be the
most distressing symptoms 35—except for pain, which
has been established to be important for palliative pa-
tients 55. Across all thirty-three oncologic studies re-
viewed, only 3 symptoms were included in almost
every version of the ESAS: pain, depression, and anxi-
ety. All other symptoms have been replaced with al-
ternatives, including gastrointestinal problems such as
constipation 13,16, and sleep-related problems such as
insomnia or difficulty sleeping 12,16,32,41. When new
items were added to the ESAS 18,29,34, investigators
sometimes found those items to be more clinically
appropriate.
Discussion of content brings into focus a question
of whether the ESAS domains exhibit “balance.” In all
versions, physical symptoms outnumber items that may
represent psycho-emotional symptoms. Patients are
likely to perceive the focus to be physical symptoms.
However, these symptoms (typically, reduced appe-
tite, nausea, drowsiness, tiredness, pain, and SOB) may
sometimes be manifestations of psychological disor-
ders or components of psychiatric diagnoses. Further,
the terms “anxiety” and “depression” may be relatively
salient because of their connotations—that is, are these
folk and non-stigmatizing language, or are they
psychiatric labels? Studies of the ESAS reveal signifi-
cant changes in depression scores within days 11,13,
which suggests that patients interpret “depression” as
a dynamic process, a feeling, or an emotion 11—al-
though in a few studies, the change may simply be a
regression-to-the-mean bias arising from the
subgrouping of patients by initial scores. Some investi-
gators have used “feelings of depression” as the
descriptor 18,34.
Finally, QOL and well-being may not be legitimate
symptoms or items for the ESAS 15,31. First, they may not
transfer accurately across cultures and languages 17. Sec-
ond, well-being may be understood to be a more psy-
chological term—an outcome of care and not a
symptom. It was originally considered to be an inter-
nal summary for all other items 51, which raises a sec-
ond aspect of “balance” between measuring negative
symptoms and deficits, and measuring positive
strengths and attributes. The focus of the ESAS is the
former, but a strict opposition or correspondence be-
tween negative and positive domains is not a require-
ment. Both may be needed for clinical management.
3.3 Theoretical Validity
The literature provides no theoretical justification for
the ESAS and its content. An argument may be made
that a theory or an overall meaning to the ESAS is not
necessary, because the goal may simply be practical:
to identify a few active symptoms using a consistent
listing and scoring system across patients.
3.4 Score Distributions
Summary baseline ESAS scores were provided in more
than half of the studies reviewed, but one third of the
thirty-nine papers did not provide mean scores or dis-
tributions by individual items. Baseline average scores
ranged from a low of 6 to a high of 75 (out of 100) for
all symptoms, but nausea was consistently the lowest-
scoring item (range: 6–28), and activity level (range:
49–75), fatigue (range: 44–67), appetite (range: 44–61),
and QOL [47 (only one study)] were the highest. In gen-
eral, mean scores were typically less than 50 out of
100, with distributions exhibiting significant “floor”
effects 14,16,17,27,31. These distributions were not sta-
tistically “normal” (being skewed, or having multiple
modes) 16. Means may vary with socio-ethnicity 33.
Mean scores this low would not be expected in pallia-
tive studies, in which investigators describe symptoms
as moderate-to-severe (although the most severe symp-
toms might not be captured with the ESAS). Possibly,
some patients interpreted the 11-point scales as having
fewer categories, were unable to distinguish adjacent
categories, or failed to understand the scale as linear
and strictly interval. Low mean scores in the ESAS re-
flected scores of exactly 0 (that is, no symptom) given
by 40%–57% of palliative patients on some items 16,17,31,
although fewer than 2% of patients scored 0 on everyESAS REVIEW
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symptom 16,27,35. Reinforcing the floor effect, investi-
gators differed with regard to the values that they took
to mean symptom absence (alternatively, prevalence),
because some used 0 to mean that a symptom was
absent, and others used a range of values (for exam-
ple, 0–2 meant either no symptom or not a clinically
significant symptom) 56.
3.5 Reliability
Studies in which multiple instruments were co-admin-
istered with the ESAS looked at a very short time of
administration, and they explored the effects of vari-
ous formats, time periods, scales, wordings, and an-
chors when asking similar questions about a symptom.
This type of reliability is often labelled “concurrent
validity,” because it demonstrates a reproducible score
despite variation in presentation.
Correlations between individual ESAS items and
scores elicited by alternative tools are fairly good, par-
ticularly for physical symptoms. Chang et al. 31 showed
that the ESAS symptoms correlating most strongly with
MSAS symptoms were SOB (0.85), appetite (0.75), nau-
sea (0.62), nervous (0.45), and depression (0.44). Simi-
larly, Moro et al. 17 showed some ESAS symptoms
correlating strongly with items in the Symptom Dis-
tress Scale (SDS) 57: nausea (0.88), SOB (0.84), pain
(0.80), appetite (0.74), and depression (0.64). Moder-
ate weighted kappa values were reported by Philip et
al. 47 for agreement with the Rotterdam Symptom
Checklist 58, including SOB (0.58), anxiety (0.48), ap-
petite (0.46), and depression (0.45). Correlation of the
Brief Pain Inventory 59 and pain was 0.61 with the ESAS
item most associated with “worst pain.”
All of the foregoing findings suggest that presenta-
tion and embedding questions inside other instruments
change scores, even for physical symptoms. Also, in
the context of a short time span, when patients were
prompted to reconsider their ESAS scores by physicians,
the inter-rater weighted kappa analysis showed strong-
est agreement for well-being (0.78), anxiety (0.72), and
depression (0.71). Overall, however, patients were
prone to revise scores up and down equally 32. Patients
may be influenced by the immediate context (that is,
the people present) or by a challenge, but this situation
could be an aspect of reliability or a method to im-
prove validity.
Reliability by test–retest with the ESAS and within
1 day is generally high, exceeding 0.8 6,11,12,31,42–43,
with the exception of one report of 0.35–0.72 21. Col-
lectively, studies have concluded that the ESAS need
not be administered more than once daily for most pal-
liative patients, even when in hospital. Repeated meas-
urements that are a full day apart give contradictory
results 17,21, representing lower reliability or a respon-
siveness to change. (Because of the dynamic nature of
symptoms in very palliative contexts, we consider re-
peated measures over longer periods of time, from 3
to 30 or more days, in the section on responsiveness.)
Proxy ratings support restricting the ESAS to elicit-
ing symptoms directly from patients. Detailed studies
by Nekolaichuk 20,21 demonstrated that physicians as-
sign scores that are lower and nurses assign scores
that are similar to those of the patient. Lower correla-
tions were apparent for subjective items of anxiety,
depression, and well-being. Correlation coefficients for
physician-or-patient ratings were weakest for activity
(0.33), depression (0.45), and well-being (0.44) 20; for
nurse-or-patient ratings, coefficients were weaker
overall, with 0.35 for activity, 0.37 for depression, and
0.23 for well-being. Interestingly, proxy scores did not
converge with patient self-scores over 2 weeks of
follow-up.
Another study 43 reported that physician and nurse
assessments were similar, but that both differed from
patient ratings.Interestingly, providers underestimated
physical symptoms and overestimated well-being, anxi-
ety, and depression. Physician-or-patient ratings had rela-
tively weak Pearson coefficients for drowsiness (0.33),
well-being (0.44), and depression (0.49), and were non-
significant for nausea and anxiety. Likewise, coefficients
for nurse-or-patient associations were weak for SOB, drow-
siness, and depression (0.32, 0.43, and 0.43 respectively).
Finally, an estimate using generalizability theory 20
suggested that 3 raters on 1 occasion or 2 raters over 2
occasions within 1 day are required to achieve accept-
able reliability. This reliability hypothesis would apply
only if patient self-reporting were not the purpose of
the ESAS.
3.6 Factor Analyses, Internal Consistency,
Summated Scoring, and Construct Validity
Associations between pairs of symptoms can imply
“structure”. Chow et al. 28 found significant Spearman
correlation coefficients between all 9 symptoms (each
p < 0.0001, coefficients ranging from 0.15 to 0.68).
Similarly, Heedman and Strang 15 found correlations
between anxiety and depression (0.76) and between
well-being and QOL (0.64). However, Teunissen et
al. 41 found no correlation between emotional and physi-
cal items.
At a larger scale than pair-wise associations, fa-
tigue, tiredness, sleep difficulties, and drowsiness might
be predicted to form one statistical factor; anxiety and
depression, another; and appetite and nausea, a third.
Three factors were uncovered at baseline for patients
with bone metastases who completed the ESAS before
radiation therapy 28: fatigue, pain, drowsiness, and well-
being; anxiety and depression; and nausea, appetite,
and SOB. Each factor had internal consistency (Cronbach
alpha values ranging from 0.68 to 0.80). During fol-
low-up after radiation, the factor structure changed,
making it impossible to generalize a factor structure
for the ESAS from this single study 28. Studies in a mixed
population of patients, including some with cancer 18,34,
confirmed that an emotional factor was distinct from a
physical factor, but otherwise, that any structure wasRICHARDSON and JONES
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unclear and not aligned with clinical experience. More
research is required to determine whether a factor struc-
ture exists and in which specific clinical contexts it
might apply.
Under an assumption that the ESAS has no factors,
the “global” internal consistency has been studied by
calculating an overall Cronbach alpha, resulting in val-
ues of 0.79 31, 0.80 29, and 0.93 48. These results sug-
gest that items are interrelated and that a combination
represents a latent construct. However, it has been
noted that, if the ESAS estimates QOL (for instance),
then it is not necessary that a patient suffer from all
symptoms to have a poor QOL, and that correlation-
based methods will be inappropriate for scale valida-
tion 17. Even so, many investigators have followed the
original suggestion 6,51 to summate item scores with
equal weighting into an index [Symptom Distress Score
(ESAS-SDS)], giving values between 0 and 100 for 10
symptoms. It was originally suggested that the sum-
mary score may represent the construct of “symptom
distress,” leading to the ESAS-SDS name 6. (Note that
this terminology should not to be confused with a defi-
nition of distress provided by the National Compre-
hensive Cancer Network, which definitely has an
emotional component 60, nor with another instrument,
the 14-item Symptom Distress Scale 17,57).
Under the assumption of one latent construct, stud-
ies of “construct validity” have been undertaken. The
meaning of construct validity varies, and for the present
review, we have taken it as an indication of whether
the ESAS estimates a physiologic or psychological con-
struct that is difficult to measure directly. No underly-
ing theory or “gold standard” instrument provides a
comparison 47 (that is, criterion validity), but the evi-
dence for an ESAS construct (“physical symptom dis-
tress”) is set out as follows:
￿ In 9 healthy subjects 37, ESAS scores were lower
than they were for patients with cancer. Another
study compared symptoms for patients with cardi-
orespiratory illnesses and cancer, and demonstrated
potentially comparable burdens of disease 34—per-
haps more with respiratory disease than with heart
disease.
￿ The ESAS-SDS distributions for hospitalized pal-
liative patients were greater than those for pallia-
tive outpatients, with values ranging from 35 to 45
(out of 100). The strongest evidence is provided by
the mean ESAS-SDS and item scores, which dif-
fered by location of care for patients managed at
the same institution (in several concurrent
nonrandomized cohort studies) 17,27,31,39. Data
from a single cohort series of patients during cura-
tive treatment had very low ESAS-SDS scores 31.
￿ The ESAS-SDS correlated with the MSAS global
distress index (0.73, p < 0.0001) and more with the
physical symptom subscales of the FACT and the
MSAS 5 than with the psychological subscales 31.
Symptom prevalence was greater with the ESAS
than with the MSAS and the FACT, but the ESAS-
SDS had a strong correlation with the MSAS physi-
cal subscale (0.74), followed by those with the
global distress index (0.73) and the total MSAS score
(0.72). A weaker yet statistically significant corre-
lation was observed between the ESAS-SDS and the
MSAS psychological subscale (0.56).
￿ The Symptom Distress Score 57 was correlated
with the ESAS-SDS (0.77), but physical items cor-
related better than psychological items did 17.
￿ Studying a renal disease population rather than a
cancer population, Davison et al. 24 demonstrated
that ESAS scores varied with the burden and the
effects of disease, but not with biochemical mark-
ers. The ESAS-SDS correlated with QOL (coeffi-
cient of 0.69).
All data regarding possible structure and internal
consistency of the ESAS suggest that the ESAS-SDS may
estimate a latent construct of “physical symptom dis-
tress.” Whether such a construct is merely physiologic
or whether it has a significant emotional component is
not established.
3.7 Convergent and Divergent Validity
The ESAS-SDS has been compared and contrasted with
summary indices from other instruments that repre-
sent other constructs:
￿ Performance Status   The ESAS-SDS was associ-
ated in several studies with KPS 15,27,31, but not
with the Eastern Cooperative Oncology Group
(ECOG) scale 29.
￿ Emotional Disorders   First, the ESAS and the Hos-
pital Anxiety and Depression Scale (HADS) 61 have
been repeatedly compared. Studies have found only
a modest association or no association between
them 14–15,35,37,41. The individual items of “anx-
ious” and “depressed” do not map well to results
with HADS, and no valid cut-offs have been estab-
lished for screening with those two ESAS items
14,41. In contrast, (although in a non-cancer popu-
lation with renal disease), Davison et al. 24 deter-
mined that the ESAS-SDS correlated more strongly
with mental (–0.62) rather than with physical (0.54)
health, as measured using the Kidney Dialysis
Quality of Life Short Form 62. The physicality of
the ESAS may therefore not be a general phenom-
enon outside oncology. Second, two recent ab-
stracts (no full publication as yet) reported only
moderate correlation (0.45) between the ESAS-SDS
and the DT in patients with cancer 63, and only
moderate correlations for items such as QOL (0.48),
nervousness (0.45), and depression (0.44) 64. No-
tably, DT is intended to estimate emotionally-re-
lated distress 60.
￿ Goals of Palliative Care   Bruera 51 demonstrated
that the ESAS-SDS was associated with the 17-item
Support Team Assessment Schedule (STAS) 65,66.ESAS REVIEW
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The STAS assesses insight, communication, plan-
ning, and aid. It is a general measure of aspects of
caring and the organization of care, and it has only
4 items regarding physical and emotional symp-
toms. The STAS and the ESAS-SDS had a correla-
tion of 0.8 (p < 0.0001).
￿ Quality of Life   The ESAS-SDS was associated
with QOL in several studies 15,29,35,48. Tierney et
al. 48 compared the ESAS with the McGill QOL
Questionnaire 67. The ESAS-SDS correlated with
the overall McGill scale (p < 0.0001), with physi-
cal well-being, and with the psychological scale
(p < 0.0001). Physical symptoms of the ESAS did
not correlate with the McGill physical domain. A
number of investigators co-administered other QOL
instruments (EORTC-Q30 38–40 and EORTC  QLQ-
PAN-26 40 and 15D QOL 16), but they did not pro-
vide statistics comparing these instruments directly
with the ESAS. Others who directly compared the
EORTC Q30 and QLQ-PAN-26 with the ESAS found
that patients preferred completing those instruments
rather than completing the ESAS 29, but no reason
was provided.
￿ Well-being   Well-being was typically included in
the ESAS, and it is strongly associated with the
overall ESAS-SDS. This finding was interpreted to
mean that the response to this item may be an over-
all outcome of the tool 6,15, supported by the find-
ing that well-being was associated with the physical
symptom scores. As an item, its location within
the ESAS (that is, surrounded by physical symp-
toms) means that the item of well-being is not a
true test of construct validity or of convergence–
divergence. However, Chang et al. 31 compared
the ESAS-SDS with the FACT general scale and
found the ESAS-SDS to be most correlated with
FACT physical well-being (–0.75), followed by QOL
(–0.69), functional well-being (–0.63), and finally
emotional well-being (–0.52).
￿ Patient Satisfaction   It was impossible to demon-
strate a statistical association between ESAS scores,
which exhibited floor effects, and patient satisfac-
tion, which exhibited ceiling effects 48.
In summary, the ESAS-SDS is moderately associ-
ated with performance status, palliative care goals,
QOL, and well-being, but it is minimally associated
with emotional symptoms and may not be associated
with patient satisfaction.
3.8 Other Statistical Associations
Another aspect of validity is whether the ESAS is asso-
ciated in predicable patterns with a diversity of vari-
ables and clinical events.
First, Bradley et al. 27 noted that younger patients
reported greater anxiety scores, that patients with
greater weight loss reported higher symptom scores,
and that pain score was associated with opiate use.
Second, the probability of documentation of symp-
toms in the medical chart was greater when patients
reported higher ESAS scores, suggesting that severity
of symptoms is associated with greater scores 38. How-
ever, although patients in another study scored the pres-
ence of symptoms, fewer of them were on medications
appropriate for those symptoms 30. Some investiga-
tors interpreted this as clinical failure, variation in
practice 36, or justification for palliative care consul-
tation 44. Such interpretations assume, rather than es-
tablish, the validity of the ESAS.
Third, several studies investigated whether the
ESAS-SDS or separate ESAS items associate with dis-
position from consultation and with overall survival.
These analyses are complicated by the possibility that
ESAS scores may have helped caregivers decide sub-
sequent clinical disposition (for example, into tertiary
care) 22. Empirically, greater ESAS scores and reduced
survival are associated in several studies 15,22,49, but
not in others 44–45. Patients with greater ESAS scores
may want fewer active interventions to prolong life.
Further, whether the ESAS adds unique information
relative to KPS 27,31 is not clear, although this asso-
ciation of the ESAS and KPS was not evident in some
studies 17,29,49. Specific items on the ESAS are known
to independently predict survival (physical symptoms
such as reduced appetite and greater dyspnea, for ex-
ample) 15,44. Although the ESAS assesses those symp-
toms and so has the potential to be associated with
overall survival, the primary purpose of the ESAS is to
manage symptoms or to audit practice, regardless of
expected survival.
3.9 Responsiveness
The ESAS has been repeatedly administered to the same
sets of patients at between 2 and 30 or more days of
follow-up. Longitudinal scores can be found in fifteen
papers 6,11,15,17,23,25–29,33,40,42,45,46. Given that some
patients were admitted for great acuity of symptoms
and for immediate care and benefit, and that others
experienced very short survival times with increasing
difficulties in completing the ESAS, such studies may
be understood as tests of positive and negative respon-
siveness. However, other interpretations are certainly
possible: for example, change in patient priorities, re-
interpretation of symptoms and anchors, and sometimes
simply a bias of regression to the mean as a result of
the method of statistical analysis.
Many studies claimed that interventions were “suc-
cessful” in reducing ESAS item scores and the overall
ESAS-SDS, but not all studies found mean scores to
decline as predicted. Most studies did not tally or
measure interventions, and they provided no data for
associations between interventions and changes in
scores 6,11,13,15,17,31,42. Heedman and Strang 36
showed no association between pain level and changes
in pain medications, but others showed that some item
scores responded to relevant interventions. ForRICHARDSON and JONES
CURRENT ONCOLOGY—VOLUME 16, NUMBER 1
59 59 59 59 59
example, a few selected case studies presented by
Bruera 23,51 nicely demonstrated the graphical use of
ESAS item scores over time to monitor symptoms and
to document effective care of individual patients. For
populations of patients, anxiety and dyspnea declined
in response to paracentesis for ascites, and both were
related to self-reported overall improvement 29. De-
tailed studies by Chow 25,26,28 provide telephone-based
follow-up scores and sequential factor analyses for up
to 12 weeks of follow-up subsequent to radiotherapy.
These follow-ups demonstrated changes in scores and
statistical factors, although the subject drop-out rate
was high.
Missing data make conclusions fragile and poten-
tially biased, but in comparing patients who responded
to radiation with patients who did not, the baseline ESAS
symptoms did not predict response to radiation, although
scores diverged in the two groups during follow-up 28.
For art therapy 33, the ESAS-SDS mean value declined,
but fewer than half of the patients approached to par-
ticipate did so, and participants were favourably dis-
posed to art therapy at baseline and may have
overestimated the benefit. Therefore, from these stud-
ies, the overall impression is that the responsiveness
of the ESAS remains questionable.
How frequently should the ESAS be administered
to patients to measure change and interpret symptoms
in follow-up 10?
Standard frequencies are not established for pa-
tients with various types of cancer, specific symptoms,
and care-delivery contexts. Only in palliative contexts,
and especially in hospitals, is daily ESAS administra-
tion reasonable, but even in that context, concern was
raised regarding the benefits of finely tracking symp-
toms when these patients are deteriorating near the end
of life 26,40,42. For example, patients stop completing
the ESAS in advance of death because of either inabil-
ity or lack of perceived benefit. Labori et al. 40 re-
ported increased symptom intensity in the last 8 weeks
before death, citing the natural elements of the termi-
nal phase of disease that inevitably worsen. Dudgeon
et al. 11 showed that overall ESAS scores improved
within 2 days, but subsequently deteriorated. Unfortu-
nately, no studies have been performed in patients re-
ceiving adjuvant curative therapies to establish a
frequency of administration.
4. DISCUSSION
The ESAS is a relatively new instrument. A number of
investigators have explicitly claimed that it has estab-
lished reliability and validity 11–17, citing several pa-
pers 6,31,47. However, Bruera et al. 6 clearly identified
the first paper on the ESAS as being only a “description
of initial experience” and provided a limited statistical
analysis that focused on the summary ESAS-SDS and
the value of the ESAS as an overall tool for auditing
care for a population of patients. Hearn et al. 3 reviewed
41 symptom-screening instruments through 1997, in-
cluding the ESAS, and concluded that, of the 12 most
relevant instruments, not one was comprehensive or
ideal. Further criteria for appraisal were listed by Sloan
et al. 68, and many reports concerning the ESAS have
been published since 1997.
Our review compiled a total of thirty-nine studies
published through 2007. Of these, thirty-three were
conducted predominantly or exclusively in the context
of cancer. Table I provides our conclusions, and we
use the remainder of this discussion to explore impli-
cations for the use of the ESAS, its further develop-
ment, and innovation to address emotional symptoms.
4.1 Using the ESAS
One possible perspective on the ESAS, without making
further modifications, is to use the tool as a limited but
systematic extension of the conventional, indeed the
venerable, “review of systems.” For this task, a “stand-
ard version of ESAS” would ensure that earlier research
findings apply. Evidence suggests that proxy assess-
ments are not substitutes for patient self-scoring of
symptoms, and so the ESAS should be administered
antecedent to clinical visits. The ESAS is brief, practi-
cal, rapid, and visual, and a numeric horizontal scale
(0–10) may be the best format. The time period to which
the questions apply should be explicit. Score reliability
is established for daily administration in the context of
palliation, in particular for certain language groupings
(English, for instance) and socio-ethnic backgrounds
(for example, white) with advanced lung and
gastrointestinal malignancies, many of whom are hos-
pitalized. Discordance is noted between clinical im-
pression (for example, severe symptoms) and actual
patient scores (for example, a significant floor effect
and low means in the score distributions); between in-
chart documentation and ESAS scores; between the tim-
ing and intensity of interventions and any change in
ESAS scores; and between ESAS scores on anxiety and
depression and scores from screening tools such as
HADS. Therefore, to determine the patient’s meaning
for any ESAS score (for example, whether the scale is
interval or merely ordinal, whether drift or resetting
of anchors occurs, and whether symptoms of greater
concern are not included in the ESAS) requires dia-
logue to turn possibly reliable and valid information
into shared knowledge. Consequently, this tool has to
be embedded within a strong clinical context such that
ESAS values can be dialogically validated and trans-
lated into actions.
A patient’s perceptions, interpretations, desires, and
expectations must be understood. First, the plain mean-
ing of all item scores has not been fully established—
for example, nausea could mean the most severe recent
nausea—although this is more a matter of refinement
of the instrument. Second, the ESAS may empower
patients only if it is relevant to them and if the clinicalESAS REVIEW
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team does it justice by paying attention to it. Third, the
meaning of an equally-weighted summary index (ESAS-
SDS) may be consistent with a latent construct of physi-
cal symptom distress (negative dimension) or with
physical well-being (positive dimension). Besides re-
sponding to the score for each individual item in isola-
tion, understanding and tracking of the summary index
of the ESAS-SDS seems appropriate.
We recommend using a standardized ESAS with
palliative patients, especially with those who are hos-
pitalized and who remain capable of completing the
instrument. The optimal way to embed the ESAS into
clinical processes and structures is still to be deter-
mined. Symptoms may then be linked with practition-
ers in respective clinical disciplines (for example,
nutrition, psychology). The purposes for which the ESAS
is best suited are the management of physical symp-
tom assessment, clinical audit, and program develop-
ment in supportive care (for example, by gathering
information).
4.2 Further Developing ESAS to Address Physical
Distress
We suggest further exploration of the role of the an-
chors and descriptors of the ESAS items to improve
clarity (for example, time period, with or without a
consideration of the effect of interventions) and to re-
distribute scores (for example, “upwards”) for statisti-
cal and interpretative purposes. Also, a test should be
made of whether a simpler scale (fewer categories
than the 11 sometimes used, or a 100-mm line) is bet-
ter than revising anchors and time periods.
One practical approach to the ESAS is to focus on
managing the items with the most extreme values
(whatever their absolute scores), and another is to un-
derstand the larger set of symptoms, even when some
are only “mild” in severity. The ability to detect preva-
lence for these purposes requires appropriate scaling,
anchors, and descriptors, possibly with labels attached
to numerically intermediate values.
TABLE I Conclusions regarding the Edmonton Symptom Assessment System (ESAS)
           Domain                                                      Conclusion or conclusions
Population characteristics Findings on reliability and validity are limited to the palliative cancer population receiving
supportive and palliative care only, especially hospitalized patients. Data in other clinical contexts
and for most languages are insufficient.
Face and content validity Too many versions of the ESAS exist, introducing an unquantifiable concern when aggregating
findings about reliability and validity across studies. The “standard” ESAS is a short patient self-
report that identifies some of the more common physical symptoms.
Theoretical validity The ESAS was not psychometrically derived within a theoretical framework. It may not be feasible
to “retrofit” a larger meaning to it from empiric findings. Lack of a theory makes the task of
identifying constructs or predicting statistical associations difficult.
Score distributions Skewed distributions improve reliability because serial responses are similar 23, but they reduce the
statistical capacity to validate the ESAS through tests of association and to establish responsiveness 16,48.
Very low symptom scores are of concern in a nonpalliative setting, in which symptom absence
ranges from 22% to 81% 31. Scales and anchors might be adjusted to try to improve score distribution.
Reliability Concurrent instruments give moderate-to-good correlations for physical symptoms, but lower
correlations for psychological–psychiatric items. The ESAS may be administered once daily in most
palliative contexts.
Structure of the ESAS By Cronbach alpha and factor analyses, the ESAS may have an internal structure, with unknown
nature, extent, and meaning. A summary score [ESAS–SDS (Symptom Distress Scale)] may estimate
“physical symptom distress.” Research into whether distress is the appropriate construct (for
example, to determine effect on emotions and higher functions such as cognition and spirituality) is
required.
Convergent and divergent validity More data are needed. The ESAS–SDS targets physical symptoms and is associated with performance
status, quality of life, physical well-being, and palliative care goals. The ESAS is less associated with
psychological and psychiatric domains. Items of anxiety and depression have no established cut-
offs for emotional–psychological screening.
Expected statistical associations This area has been poorly studied.
Responsiveness Responsiveness is a function of reliability and validity. Scores on the ESAS vary inconsistently with
interventions. The frequency of completing the ESAS to measure change is unknown.RICHARDSON and JONES
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We recommend that the number of physical symp-
toms be increased from 7 to at least 10, with items such
as constipation and dry mouth being possible additions
with wide relevance. In addition to large systematic
surveys of symptoms, qualitative research (that is, fo-
cus groups) may be required to identify important items.
Expanding the list of symptoms would reduce the need
for investigators to constantly modify the ESAS or to sup-
plement it with interviews for additional symptoms.
However, the physical symptoms privileged by their in-
clusion in the ESAS should not be redundant (that is, from
among the same symptom clusters or statistical fac-
tors), so that the ESAS can remain brief, efficient, and
simple. The ESAS should target the symptoms with great-
est meaning or clinical implication—that is, those that
cause important physical symptom distress reliably rep-
resenting clustered symptoms that can be managed or
treated or that have prognostic significance. To increase
internal consistency (or factorization) and to strengthen
the ESAS-SDS in its estimation of “physical symptom
distress,” we recommend removing items such as QOL,
well-being, anxiety, and depression from the ESAS and
replacing them with more physically-oriented items.
Conceivably, items could also be added to assess the
effect of physical symptoms on other dimensions (for
example, cognition, spiritual suffering, and the emotions
representing disruptive physical symptoms), and to de-
termine physical strengths (for example, exercise ca-
pacity or tolerance) that may help in management.
Although physical symptoms may interact and com-
plicate management, a “first approximation” to man-
aging core physical symptoms is to assume that they
are entirely physical and can be effectively managed
in isolation. This practical approach is an extension of
the current model of supportive care. Cut-off values to
categorize severity (mild, moderate, severe) have not
been validated for the ESAS, and so sorting patients for
various interventions by ranges of scores is problem-
atic. There are probably more ESAS values (11) than
there are clinical responses. Although physical symp-
toms and processes are the focus, interventions could
include psychosocial and behavioural actions—for ex-
ample, managing fatigue and sleep disturbances.
To build positively on the existing success of the
ESAS, a revised ESAS is a research priority. To estab-
lish reliability and validity, a cumulative research pro-
gram will be required, particularly in the contexts of
newly diagnosed patients and ambulatory care.
4.3 Addressing Emotional Symptoms
We conclude that the emotional components in the ESAS
are underdeveloped and require extensive modifica-
tion. Patients recently diagnosed with cancer and those
undergoing treatment for cancer often suffer high lev-
els of emotional symptoms, with many patients fur-
ther developing clinical disorders of anxiety, depression,
and post-traumatic distress 69. Many experience diffi-
culty coping that extends into survivorship: one quarter
of all cancer-free survivors suffer from psychiatric dis-
orders 69. A patient with cancer will not experience
isolated symptoms with individual causes, but will ex-
perience a complex combination of interacting physi-
cal and emotional symptoms regardless of causation,
which complicates management. When only a
physiologic perspective is used, considerable difficulty
arises in interpreting scores for physical symptoms.
And even if the meaning of the scores are the same
across patients, those patients may not report the same
scores when experiencing the same level of symptoms.
Some patients may not want to divulge symptoms that
can jeopardize cancer treatment (for example, depres-
sion); others may want to avoid symptoms, being un-
able to face the mortality that such symptoms imply
(emotional “repressors”) 70. For these reasons, each
item’s score or range of scores may have various mean-
ings and correspondingly various implications for care.
This understanding reinforces the established observa-
tion that no clear cut-offs for screening have been de-
termined for the ESAS scales. The rich information that
an 11-point ESAS scale for physical symptoms provides
to the clinician would be lost by simplistic reduction to
errant categories of mild, moderate, and severe, and
by ignorance of the associated emotions and meaning.
To address emotional symptoms, we recommend
innovation through the development of a separate tool,
similar to the ESAS, that addresses 10 or more emo-
tional symptoms, that uses nonpsychiatric labels, and
that encompasses symptoms representing more disor-
ders than just anxiety and depression. This new instru-
ment would inject the ESAS into a theoretical
framework in which physical and emotional symptoms
associate for reasons of causality and interaction and
for which interpretation of item values requires, at a
minimum, an understanding of both physiology and
psycho-emotional processes. Whether an existing
“emotional” tool may be sufficient for this task is un-
known. The hope is that concurrently administering a
complementary pair of ESAS-physical and ESAS-emo-
tional questionnaires could provide a more nuanced and
useful interpretation for front-line staff.
The interjection of a new technology such as the
ESAS presents methodology, resource, interpretative,
scope-of-practice 71, and ethical-medico-legal chal-
lenges 72. We consider the ESAS to be a step in the
right direction, but research regarding validity of the
ESAS outside a palliative context is limited. Further
elaboration of the ESAS with the goal of measuring more
physical symptoms and related “distress,” and of meas-
uring emotional symptoms are research priorities.
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